Gaudium IVF AND Women Health Limited IPO
About Gaudium IVF AND Women Health Limited
The company is engaged in IVF (In vitro fertilization) treatment in India and has grown into several states with Hub and spoke model over the years. The company operates 30+ locations, which comprises of 7 hubs (centers) and 28 spokes (company has entered into a strategic alliance with Spokes i.e Infertility Expert to achieve the mutual goal of spreading awareness about ART and IVF treatment). Its treatments include In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI) and ovulation induction, all its treatment is carefully designed to address a variety of infertility challenges for both male and female.
IPO Details
1.46
₹75.00 - 79.00
189
₹14,931
TBA
IPO
BSE
INE0P8B01020
- (-)
IPO Timeline
Subscription Details
-x
-x
-x
-x
Gaudium IVF AND Women Health Limited Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 189 | ₹14,931 |
| Retail (Max) | 1 | 189 | ₹14,931 |
| HNI (Min) | 2 | 378 | ₹29,862 |
Strengths of Gaudium IVF AND Women Health Limited
- Patient Centric Approach
- Expert Team
- Modern Technology
- Highly Technical USG Guided Services
- Payment Options
- Asset Light Business Model
- Hubs in major Cities
- Spokes Nearby Hubs
Weakness of Gaudium IVF AND Women Health Limited
- As on date, it have contingent liabilities of ₹4,499.34 lakhs (including interest thereon) on vis-a-vis net worth of ₹5,885.47 lakhs for the period ended September 30, 2025 that have not been provided for and commitments in its financial statements, which if materialize, may adversely affect its financial condition.
- The Company is in engaged in the business of providing healthcare services mainly rendering various fertility treatments such as In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Sperm Injection (ICSI), Egg Freezing, laser assisted embryo implantation amongst others and is subject to various operational, reputational, medical and legal risks associated with the operations of healthcare services. An inability to provide quality healthcare catering to the needs of the customers could adversely affect the reputation, business prospects and financial performance of the Company.
- The Company is highly dependent on doctors, nurses and other healthcare professionals and the business will be impacted significantly if the Company is unable to attract / retain such professionals. The attrition rate of the employees during the period ended September 30, 2025, Fiscal 2025, Fiscal 2024 and Fiscal 2023 was 31%, 63%, 51% and 51%. Further, the Professional and Consultation fees paid to doctors as a percentage of its total expenses were 6.08%, 8.28%, 12.23% and 13.78%, for the period ended September 30, 2025 and for Fiscal 2025, Fiscals 2024 and 2023.
- The Company have entered, and will continue to enter, into related party transactions which may potentially involve conflicts of interest.
- They are dependent on limited embryologists and the loss of or its inability to attract or retain such personnels could adversely affect its business, financial condition and results of operations.
FAQs on Gaudium IVF AND Women Health Limited IPO
What are allotment date for the Gaudium IVF AND Women Health Limited ?
Allotment: 25-02-2026
What are the open and close dates for the Gaudium IVF AND Women Health Limited IPO ?
Opens on 20-02-2026, closes on 24-02-2026.
Can NRIs apply for the Gaudium IVF AND Women Health Limited IPO through PL Capital?
Yes, NRIs can apply for the Gaudium IVF AND Women Health Limited IPO through PL Capital, subject to RBI and SEBI guidelines. Applications can be made via the NRE or NRO account route.
Where is the Gaudium IVF AND Women Health Limited IPO getting listed?
The Gaudium IVF AND Women Health Limited IPO will be listed on BSE. The exact listing date is 27-02-2026.
What is the minimum and maximum investment allowed in the Gaudium IVF AND Women Health Limited IPO?
The minimum investment for retail investors in the Gaudium IVF AND Women Health Limited IPO is ₹14,931. The maximum retail investment allowed is ₹14,931.
What is the GMP for this IPO?
Current GMP is - (-)
